Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1996066 | 0.82 | MEN1 (0.35) | MEN1KMT2ACES2CES1 | |
| SCHEMBL29443097 | 0.77 | PDE2A (0.34) | CYP11B2PDE2ALMNAMEN1KMT2A | |
| SCHEMBL22905071 | 0.77 | PDE2A (0.34) | CYP11B2PDE2ALMNAMEN1KMT2A | |
| SCHEMBL1996784 | 0.77 | MEN1 (0.37) | CYP11B2PDE2AMAPTMEN1KMT2A | |
| SCHEMBL2428667 | 0.74 | TSHR (0.37) | CYP11B2PDE2ALMNAHPGDMEN1 | |
| SCHEMBL2424298 | 0.73 | MEN1 (0.35) | CYP11B2PDE2AMEN1KMT2A | |
| SCHEMBL27248110 | 0.73 | GABRA1 (0.38) | CYP11B2PDE2AMEN1KMT2AKDM4E | |
| SCHEMBL22129200 | 0.72 | MEN1 (0.34) | LMNAMEN1KMT2A | |
| SCHEMBL3104509 | 0.72 | PDE2A (0.34) | CYP11B2PDE2ALMNAMEN1KMT2A | |
| SCHEMBL19137101 | 0.72 | CES2 (0.37) | CYP11B2PDE2ASMN1; SMN2CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1203760-B1 | Method for producing cyclopropanecarboxylates | SUMITOMO CHEMICAL CO (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-6706910-B2 | BY TRANSESTERIFICATION OF A CYCLOPROPANECARBOXYLATE AND A MONOHYDROXY COMPOUND IN THE PRESENCE OF A LITHIUM ALKOXIDE OR LITHIUM ARYLOXIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-03-16 | — | — | US | disclosed |
| EP-1203760-A1 | Method for producing cyclopropanecarboxylates | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-05-08 | — | — | EP | disclosed |
| US-20020052525-A1 | Method for producing cyclopropanecarboxylates | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052525-A1 | Method for producing cyclopropanecarboxylates | CYP8B1, SRD5A2, CYP21A2 | CYP11B2 9/4885PDE2A 2812/4885LMNA 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.